Patents

New manufacturing patent issued for AIDS vaccine, cystic fibrosis and arthritis programs

Published in Gene Therapy Weekly, June 19th, 2003

Targeted Genetics Corporation (NASDAQ:TGEN) announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector manufacturing process. U.S. Patent No. 6,566,118 is titled, "Methods for generating high titer helper-free preparation of released recombinant AAV vectors."

The patent describes an AAV manufacturing process in which the growth conditions used to culture the production cells lead to the release of vector particles into the cell culture medium without the need for breaking open the host cell membrane. This approach leads to improved production quality and allows for a more cost-effective approach to large-scale manufacturing of AAV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry